EAN 2025 | Including central vein sign in McDonald criteria to distinguish MS from similar diseases
Celia Oreja-Guevara, MD, PhD, University Hospital San Carlos, Madrid, Spain, comments on the inclusion of the central vein sign in the McDonald diagnostic criteria for multiple sclerosis (MS). This sign is useful for differentiating MS from neuromyelitis optica (NMO), but its utility is limited in differentiating MS from myelin oligodendrocyte glycoprotein autoimmune disease (MOGAD). This interview took place at the 11th Congress of the European Academy of Neurology (EAN 2025) in Helsinki, Finland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
This year we hope that we will publish the new criteria of McDonald’s and one of the important things is the inclusion of the detection of the central vein sign in this new criteria of McDonald’s. What is important is because we want to differentiate MS from other diseases so that we can detect now this central vein sign that it means that it’s in a lesion that is coming through a vein and we can detect the vein...
This year we hope that we will publish the new criteria of McDonald’s and one of the important things is the inclusion of the detection of the central vein sign in this new criteria of McDonald’s. What is important is because we want to differentiate MS from other diseases so that we can detect now this central vein sign that it means that it’s in a lesion that is coming through a vein and we can detect the vein. The new criteria say that the patients they have more than six lesions with the central vein sign they will have multiple sclerosis and we have presented that we have studied around 50 patients and the patients with MS, all of them, they have more than six lesions with the central vein sign. We have a look at patients with NMO and the patients with NMO, they have no central vein sign. So that is a very good thing to differentiate between MS and NMO. The problem is that we have some patients with MOGAD and these patients with MOGAD, some of them they have the central vein sign and some of them they have more than six. So it means the central vein sign is useful to differentiate between MS and NMO, but it’s more difficult to differentiate from MOGAD so that when we want to differentiate from MOGAD, we need to do other additional tests.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
C Oreja-Guevara received honoraria for speaking, consulting and serving on advisory boards from Alexion, Amgen, Biogen Idec, BMS, Horizon, Janssen, Merck, Novartis, Roche, Sanofi-Genzyme, Sandoz, Viatris, Neuraxpharm and Teva.
